Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG.

The aberrant expression of the Tn antigen (CD175) on surface glycoproteins of human carcinomas is associated with tumorigenesis, metastasis, and poor survival. To target this antigen, we developed Remab6, a recombinant, human chimeric anti-Tn-specific monoclonal IgG. However, this antibody lacks antibody-dependent cell cytotoxicity (ADCC) effector activity, due to core fucosylation of its N-glycans. Here we describe the generation of an afucosylated Remab6 (Remab6-AF) in HEK293 cells in which the FX gene is deleted (FXKO). These cells cannot synthesize GDP-fucose through the de novo pathway, and lack fucosylated glycans, although they can incorporate extracellularly-supplied fucose through their intact salvage pathway. Remab6-AF has strong ADCC activity against Tn+ colorectal and breast cancer cell lines in vitro, and is effective in reducing tumor size in an in vivo xenotransplant mouse model. Thus, Remab6-AF should be considered as a potential therapeutic anti-tumor antibody against Tn+ tumors. © 2023. The Author(s).

Citation

Yasuyuki Matsumoto, Nan Jia, Jamie Heimburg-Molinaro, Richard D Cummings. Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG. Scientific reports. 2023 Mar 28;13(1):5027

Mesh Tags

Substances

PMID: 36977722

search → result